Episode 72: Nefecon for IgAN, The NefIgArd part B trial

<p>The Filtrate:</p><p><strong>Joel Topf</strong></p><p><strong>Josh Waitzman</strong></p><p>With Special Guest:</p><p><strong>Brad Rovin</strong> (<a href="https://twitter.com/bradrovin">@BradRovin</a>) Chief of nephrology at The Ohio State University Wexner Medical Center, one of the authors of the Nefigard trial. </p><p><strong>Koyal Jain </strong>(<a href="https://x.com/koyaljainmd?lang=en">@koyaljainMD</a>) Program director of the GN Fellowship at University of North Carolina</p><p><strong>Roger Rodby</strong> (<a href="https://twitter.com/NephRodby">@NephRodby</a>) Associate program director of the Rush University Nephrology Fellowship</p><p>Editor </p><p><strong>Sophia Ambruso</strong></p><p><strong>Show Notes</strong></p><p>The manuscript (<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01554-4/abstract">The Lancet </a>| <a href="https://pubmed.ncbi.nlm.nih.gov/37591292/">PubMed</a> | <a href="http://www.nephjc.com/news/nefigard-final">NephJC</a>)</...